Company profilePharmaceutical#328 of 1,318 in Pakistan✓ No DRAP alerts

JINNAH PHARMACEUTICALS

Pharmaceutical company · 54 brands · 61 molecules

Ranked #216 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

54 registered products 23 pharmaceutical brands 61 distinct molecules 0 DRAP alerts

Company overview

54
registered products
23
pharmaceutical brands
61
distinct molecules
12
therapeutic classes
0
DRAP alerts

JINNAH PHARMACEUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 54 product registrations across 61 distinct molecules. Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Blood Glucose Lowering Drugs, Excluding Insulin. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Paracetamol4 brands
Ethambutol3 brands
Isoniazid3 brands
Pyrazinamide2 brands
Rifampicin2 brands
Diclofenac2 brands
Mefloquine1 brand

Therapeutic classes

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Blood Glucose Lowering Drugs, Excluding Insulin · 2Antimalarials · 1Antiemetics & Antinauseants · 1Angiotensin-Ii Antagonists, Combinations · 1Antianemic, Iron Preparations · 1Lipid Modifying Agents · 1Quinolone Antibacterials · 1Antidiarrheals, Intestinal Antiinflammatory/Antiinfective · 1Antimycobacterials (Antituberculosis) · 1Beta-Lactam Antibacterials, Penicillins · 1Antihistamines For Systemic Use · 1

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for JINNAH

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.